| Product Code: ETC13340853 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
Europe mRNA Vaccines and Therapeutics Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Europe mRNA Vaccines and Therapeutics Market Overview |
3.1 Europe Regional Macro Economic Indicators |
3.2 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Europe mRNA Vaccines and Therapeutics Market - Industry Life Cycle |
3.4 Europe mRNA Vaccines and Therapeutics Market - Porter's Five Forces |
3.5 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Vaccine Type, 2021 & 2031F |
3.7 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Therapeutic Type, 2021 & 2031F |
3.8 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Delivery Method, 2021 & 2031F |
3.10 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Europe mRNA Vaccines and Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Europe mRNA Vaccines and Therapeutics Market Trends |
6 Europe mRNA Vaccines and Therapeutics Market, 2021 - 2031 |
6.1 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By COVID-19 Vaccine, 2021 - 2031 |
6.1.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Influenza Vaccine, 2021 - 2031 |
6.1.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Rabies Vaccine, 2021 - 2031 |
6.1.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Zika Virus Vaccine, 2020 - 2028 |
6.1.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By CMV Vaccine, 2020 - 2028 |
6.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Cancer Immunotherapy, 2021 - 2031 |
6.2.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Personalized Cancer Vaccine, 2021 - 2031 |
6.2.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Protein Replacement Therapy, 2021 - 2031 |
6.2.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Autoimmune Disease Treatment, 2021 - 2031 |
6.2.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By mRNA-Based Drug Delivery, 2020 - 2028 |
6.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Infectious Diseases, 2021 - 2031 |
6.3.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Oncology, 2021 - 2031 |
6.3.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Genetic Disorders, 2021 - 2031 |
6.3.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Neurological Disorders, 2021 - 2031 |
6.3.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Cardiovascular Diseases, 2021 - 2031 |
6.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Intramuscular Injection, 2021 - 2031 |
6.4.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Subcutaneous Injection, 2021 - 2031 |
6.4.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Intradermal Injection, 2020 - 2028 |
6.4.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Intravenous Infusion, 2020 - 2028 |
6.4.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Oral Delivery, 2020 - 2028 |
6.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Hospitals, 2020 - 2028 |
6.5.3 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Clinics, 2020 - 2028 |
6.5.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Research Institutes, 2020 - 2028 |
6.5.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Biotechnology Firms, 2020 - 2028 |
6.5.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Pharmaceutical Companies, 2020 - 2028 |
7 Europe mRNA Vaccines and Therapeutics Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.1 United Kingdom (UK) mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.2 Germany mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.3 France mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.4 Poland mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.5 Spain mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.2.6 Rest of Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Vaccine Type, 2021 - 2031 |
7.3 Europe mRNA Vaccines and Therapeutics Market Revenues & Volume Share, By Therapeutic Type, 2021 & 2031F |
7.3.1 United Kingdom (UK) mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.3.2 Germany mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.3.3 France mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.3.4 Poland mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.3.5 Spain mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.3.6 Rest of Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Therapeutic Type, 2021 - 2031 |
7.4 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.1 United Kingdom (UK) mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.2 Germany mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.3 France mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.4 Poland mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.5 Spain mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4.6 Rest of Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.1 United Kingdom (UK) mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.2 Germany mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.3 France mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.4 Poland mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.5 Spain mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.5.6 Rest of Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By Delivery Method, 2021 - 2031 |
7.6 Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.1 United Kingdom (UK) mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.2 Germany mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.3 France mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.4 Poland mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.5 Spain mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.6 Rest of Europe mRNA Vaccines and Therapeutics Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Europe mRNA Vaccines and Therapeutics Market Key Performance Indicators |
9 Europe mRNA Vaccines and Therapeutics Market - Export/Import By Countries Assessment |
10 Europe mRNA Vaccines and Therapeutics Market - Opportunity Assessment |
10.1 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By Vaccine Type, 2021 & 2031F |
10.3 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By Therapeutic Type, 2021 & 2031F |
10.4 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By Application, 2021 & 2031F |
10.5 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By Delivery Method, 2021 & 2031F |
10.6 Europe mRNA Vaccines and Therapeutics Market Opportunity Assessment, By End User, 2021 & 2031F |
11 Europe mRNA Vaccines and Therapeutics Market - Competitive Landscape |
11.1 Europe mRNA Vaccines and Therapeutics Market Revenue Share, By Companies, 2022 |
11.2 Europe mRNA Vaccines and Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here